This post was originally published on this site
The company submitted to the health agency all modules required for the evaluation of NVX-CoV2373, its protein-based COVID-19 vaccine, days after receiving its first emergency use authorization from Indonesia.
The company is also expecting regulators in countries including India and the Philippines to decide on its vaccine within weeks.
A green light from the WHO would set the stage for Novavax to begin shipping doses to the COVAX program that supplies shots to low-income countries.
Novavax is prepared to deliver its vaccine globally, Chief Executive Stanley Erck said in a statement. The company said it remains on track to file for U.S. approval by end of the year.
The Maryland-based vaccine developer reported a bigger net loss of $322.4 million, or $4.31 per share, for the third quarter, compared to $197.3 million a year earlier.
Revenue rose to $178.8 million, mainly due to increased development activities relating to its COVID vaccine, including services performed under the U.S. government agreement and royalties from licensing pacts.
